Lachman Consultants

Executive Summary

Lachman Consultants is a specialized regulatory and quality consulting firm serving the pharmaceutical, biologics, and medical device industries. Founded in 1978 and headquartered in Westbury, New York, the company leverages a team of former senior FDA officials and industry experts to help clients navigate complex regulatory pathways, prepare for inspections, and accelerate product approvals. Its services include compliance audits, regulatory affairs strategy, mock FDA inspections, and scientific consulting. With over four decades of experience, Lachman has built a reputation for deep regulatory expertise and practical guidance, particularly in areas such as drug delivery, digital health, and AI/ML integration. The firm's client base ranges from emerging biotechs to established pharmaceutical companies, all seeking to mitigate regulatory risk and expedite time-to-market. As regulatory frameworks evolve globally, Lachman's advisory role becomes increasingly critical, positioning it to benefit from secular trends in drug development complexity and regulatory scrutiny. Looking ahead, Lachman Consultants is well-positioned to capitalize on several growth drivers. First, the ongoing FDA modernization and PDUFA VII reauthorization are expected to introduce new review standards and compliance requirements, driving demand for consulting services. Second, the firm's expertise in AI/ML for drug development and digital health aligns with the FDA's emerging guidance on these technologies, opening new service lines. Third, the increasing complexity of global regulatory harmonization (e.g., ICH guidelines) creates opportunities for cross-border compliance support. While Lachman operates in a competitive landscape with larger players like IQVIA, its niche focus and senior-level talent provide differentiation. Overall, the company's stable business model and recurring revenue from compliance audits support a solid conviction score.

Upcoming Catalysts (preview)

• 2027-2028PDUFA VII Reauthorization and FDA Modernization90% success
• 2026-2027Launch of AI/ML Regulatory Consulting Practice75% success
• 2026-2028Increased Demand from Biosimilar and Cell/Gene Therapy Approvals80% success